

January 18, 2024



D.C. Update: NASDAD Presents Friend of NASADAD Award to SAMHSA's Tom Coderre, FDA Announces Shelf-Life Extension for Naloxone Nasal Spray, CDC Foundation Releases Cigarette Sales Briefs, and More.

[Visit our Website](#)



Meet The Member

Grace Kindt, National Prevention Network (NPN) Coordinator for Pennsylvania

Grace Kindt is the Prevention Section Chief at the Pennsylvania Department of Drug & Alcohol Programs (DDAP). Grace also serves as the National Prevention Network (NPN) Coordinator for Pennsylvania. She has worked in DDAP's Prevention Section for the last 13 years. In her role, she oversees the 20% set aside prevention component of the Substance Use Prevention, Treatment, and Recovery Services (SUPTRS) Block Grant in addition to other State and federal prevention funding. She also helps to oversee the Pennsylvania Student Assistance Program, the Pennsylvania Youth Survey, the State Epidemiological Outcomes Workgroup, and various other initiatives. Grace also leads the national Prevention Survey Consortium that was launched in 2023 to provide States a space to share survey innovations and ideas and discuss survey challenges and solutions. Ms. Kindt earned her Master's in Public Health from the University at Albany and is Certified in Public Health.



NASADAD News

NASDAD Presents Friend of NASADAD Award to SAMHSA's Tom Coderre

On Tuesday, January 16, NASADAD's Robert Morrison

met with Tom Coderre, Principal Deputy Assistant Secretary at the Substance Abuse and Mental Health Services Administration (SAMHSA), to present the 2023 “Friend of NASADAD Award” for his partnership with State alcohol and drug agencies and the Association. NASADAD held a virtual ceremony in December to honor all awardees. While Tom was not available to participate in the event, he did share a video offering remarks. NASADAD wished to hand-deliver the award given Tom’s leadership and commitment to working with States.

Congratulations Tom. NASADAD appreciates your work.



Around the Agencies

FDA Announces Shelf-Life Extension for Naloxone Nasal Spray

On Wednesday, January 17, the Food and Drug Administration (FDA) announced that Emergent BioSolutions, the manufacturer of over-the-counter (OTC) NARCAN Naloxone Nasal Spray for opioid overdose reversal, is extending the shelf-life of newly manufactured NARCAN 4 milligram (mg) Nasal Spray products from 3-years to 4-years. The FDA’s shelf-line extension applies only to NARCAN 4 mg Nasal Spray products produced in the future; products that have already been produced and distributed prior to the extension will not be affected and the expiration date listed on the product should be followed. The extension was announced at the request of the FDA as part of the FDA’s Overdose Prevention Framework that seeks to prevent overdoses and reduce overdose-related deaths by expanding access to overdose reversal agents.

NARCAN 4 mg Nasal Spray is the first naloxone product approved for OTC, nonprescription use in March 2023. The FDA approved an initial shelf-life extension for NARCAN 3 mg Nasal Spray in August 2020 to 3-years.

The FDA’s press release announcing the shelf-life extension can be found [here](#).

IHS Funding Opportunity: Community Opioid Intervention Prevention Program

The Department of Health and Human Services’ (HHS) [Indian Health Service \(IHS\)](#) recently announced a new funding opportunity for the [Community Opioid Intervention Prevention Program](#). The grant program aims to develop culturally appropriate responses to address opioid use disorder (OUD) in American Indian and Alaska Native (AI/AN) communities specifically. In particular, the program intends to address the opioid crisis in AI/AN communities by:

1. “...developing and expanding community education and awareness of prevention, treatment, and recovery activities for opioid misuse and opioid use disorder;
2. increasing knowledge and use of culturally appropriate interventions and to encourage an increased use of medication-assisted treatment/medications for opioid use disorder (MAT/MOUD);
3. supporting Tribal and Urban Indian communities in their effort to provide prevention, treatment, and recovery services to address the impact of the opioid crisis; and
4. increase harm reduction within their communities.”

IHS will offer up to 27 awards of up to \$350,000 per award, per year, for a five-year project. Details on eligibility can be found [here](#).

Applications are due February 7. Apply [here](#).



CDC Foundation Releases National and State Cigarette Sales Brief

The Centers for Disease Control and Prevention (CDC) Foundation recently released a brief on [Changes in US and State Cigarette Sales Following Flavored Tobacco Sales Restrictions](#). The data brief explores changes in national and State cigarette sales following implementation of State flavored tobacco sales restrictions across the country. Specifically, these briefs provide estimates of population trends of cigarette sales in the overall U.S. market when compared to select States from 2018 to 2023. This data does not include online tobacco sales or specialty stores. The brief is part of the Monitoring E-Cigarette Use Among Youth in Select U.S. Cities and States program that aims to assess the effectiveness of e-cigarette flavor restriction policies. Key findings include:

- “Cigarette sales declined substantially during the past 5 years, and declined more in states with comprehensive laws that prohibit the sale of most flavored tobacco products, including flavored e-cigarettes and menthol cigarettes.
- Cigarette sales declined in states with laws prohibiting the sale of flavored e-cigarettes, but these declines were more modest than the declines in states with comprehensive flavored tobacco restrictions.”

The data brief can be downloaded in full [here](#).

CoE-PHI Resource: Sharing SUD Treatment Records with Multiple Providers: How to Use Multi-Party Consent Forms



The Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center of Excellence for Protected Health Information (CoE-PHI) recently released a resource on [Sharing SUD Treatment Records With Multiple Providers: How to Use Multi-Party Consent Forms](#). This resource aims to provide guidance on how to fill out consent forms to authorize the disclosure of substance use disorder (SUD) treatment records to multiple parties in compliance with Part 2 of the Health Insurance Portability and Accountability Act (HIPPA) Privacy Rule. Key takeaways include:

- “Multi-party consent forms work best when a patient wants to authorize different people to receive the same information for the same purpose.
- Multi-party consent forms should be avoided when the parties need different information for different purposes.
- When using a multi-party consent form, it can be useful to authorize disclosures between all the parties - not just one-way disclosures from a Part 2 program to other parties.”

The new resource can be downloaded [here](#).

Webinars to Watch

COSSUP Webinar: Insights From the Frontline - Police-led Deflection Programs

The Bureau of Justice Assistance’s (BJA) Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP), in collaboration with the Center for Health Justice (CHJ) at Treatment Alternatives for Safe Communities (TASC) and the International Association of Chiefs of Police (IACP), is hosting a webinar on [Insights From the Front Line - Police-led Deflection Programs](#). This no-cost webinar is on January 22, at 2:00 pm ET. The webinar will feature presentations from various police departments, which will highlight the benefits of deflection to treatment and other services to address substance use disorder (SUD), their department’s deflection work, and best practices for collaborating with community partners. Registration is required.

ORN Webinar: Innovations in the Treatment of Opioid Use Disorder in Pregnancy

The Opioid Response Network (ORN), in collaboration with

the Boston Medical Center Grayken Center for Addiction Training and Technical Assistance, is hosting a webinar on [*Innovations in the Treatment of Opioid Use Disorder in Pregnancy*](#). This no-cost webinar is on January 23, at 12:00 pm ET. The webinar aims to review the use of medications for opioid use disorder (MOUD) in pregnancy with an emphasis on the evidence supporting its benefits and risks, as well as evidence for the use of long-acting injectable options for MOUD in perinatal patients. Specifically, the webinar's objectives are to:



**Opioid
Response
Network**

- “Recall the evidence supporting the use of long-acting injectable buprenorphine in perinatal patients.
- Review the evidence supporting the use of naltrexone in perinatal patients.
- Recall the risk vs benefit of continuing medication for opioid use disorder in pregnancy.”

Registration is required.

NASADAD | 1919 Pennsylvania Avenue NW, Suite M 250, Washington, DC 20006

[Unsubscribe ladams@nasadad.org](mailto:ladams@nasadad.org)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by ladams@nasadad.org powered by



Try email marketing for free today!